In This Article:
Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services.
The partnership will leverage Samsung Biologics' new ADC facility to support the development of a series of LigaChem's ADC programmes.
The deal builds on an existing collaboration in place between the two companies to develop ADC programmes for solid tumours.
LigaChem Biosciences president and CEO Yong-Zu Kim stated: “This collaboration with Samsung Biologics will be an important step toward strengthening the supply chain of high-quality ADC drugs and enhancing the competitiveness of both companies in the global ADC market.
“By leveraging Samsung Biologics' extensive experience as a CDMO [contract development and manufacturing organisation], we will accelerate the development of our pipeline and quickly provide innovative ADC treatments to patients".
Samsung Biologics' ADC facility is a segregated suite equipped with a 500l reactor.
The facility supports the development and manufacturing process of ADC therapies, from late discovery and development to conjugation.
Samsung Biologics CEO and president John Rim stated: “The latest collaboration will further strengthen Samsung Biologics' capabilities across all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapeutics to patients.
“We look forward to supporting our clients' innovative ADC pipelines, ensuring the highest quality and timelines are met.”
Samsung Biologics has been investing in biotech companies through the Samsung Life Science Fund.
These investments are directed towards companies working on new ADC linker technologies, toolbox and protein engineering.
In November 2024, Samsung Biologics entered a manufacturing agreement, securing a $668m contract with a Europe-based pharmaceutical company.
"Samsung Biologics and LigaChem extend ADC services deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.